Gland Pharma Future Growth
Future criteria checks 4/6
Gland Pharma is forecast to grow earnings and revenue by 25.8% and 11.1% per annum respectively. EPS is expected to grow by 25.9% per annum. Return on equity is forecast to be 11% in 3 years.
Key information
25.8%
Earnings growth rate
25.9%
EPS growth rate
Pharmaceuticals earnings growth | 17.8% |
Revenue growth rate | 11.1% |
Future return on equity | 11.0% |
Analyst coverage | Good |
Last updated | 05 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 76,955 | 13,132 | 8,386 | 10,337 | 9 |
3/31/2026 | 68,952 | 11,035 | 7,270 | 9,273 | 10 |
3/31/2025 | 61,154 | 8,164 | 5,429 | 6,807 | 10 |
9/30/2024 | 58,901 | 6,916 | 8,195 | 12,187 | N/A |
6/30/2024 | 58,577 | 7,221 | N/A | N/A | N/A |
3/31/2024 | 56,647 | 7,725 | 5,985 | 9,968 | N/A |
12/31/2023 | 49,123 | 6,587 | N/A | N/A | N/A |
9/30/2023 | 43,054 | 6,988 | 832 | 3,901 | N/A |
6/30/2023 | 39,764 | 7,460 | N/A | N/A | N/A |
3/31/2023 | 36,246 | 7,810 | 1,408 | 3,640 | N/A |
12/31/2022 | 39,426 | 9,883 | N/A | N/A | N/A |
9/30/2022 | 40,676 | 10,293 | 6,747 | 9,508 | N/A |
6/30/2022 | 41,037 | 10,902 | N/A | N/A | N/A |
3/31/2022 | 44,007 | 12,117 | 2,687 | 7,908 | N/A |
12/31/2021 | 41,854 | 11,862 | N/A | N/A | N/A |
9/30/2021 | 39,815 | 11,172 | 328 | 4,688 | N/A |
6/30/2021 | 37,326 | 10,340 | N/A | N/A | N/A |
3/31/2021 | 34,629 | 9,970 | 3,762 | 6,049 | N/A |
12/31/2020 | 32,104 | 9,313 | N/A | N/A | N/A |
6/30/2020 | 28,430 | 9,027 | 7,025 | 9,058 | N/A |
3/31/2020 | 26,332 | 7,729 | 5,063 | 7,009 | N/A |
3/31/2019 | 20,442 | 4,519 | 495 | 1,853 | N/A |
3/31/2018 | 16,199 | 3,211 | N/A | 2,021 | N/A |
3/31/2017 | 14,792 | 4,137 | N/A | 4,765 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 543245's forecast earnings growth (25.8% per year) is above the savings rate (6.7%).
Earnings vs Market: 543245's earnings (25.8% per year) are forecast to grow faster than the Indian market (17.9% per year).
High Growth Earnings: 543245's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 543245's revenue (11.1% per year) is forecast to grow faster than the Indian market (10.4% per year).
High Growth Revenue: 543245's revenue (11.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 543245's Return on Equity is forecast to be low in 3 years time (11%).